{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:59:40Z","timestamp":1790139580839,"version":"4.0.1"},"reference-count":168,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001809","name":"\"Special Fund for Agroscientific Research in the Public Interest (National Natural Science Foundation of China)","doi-asserted-by":"publisher","award":["201503135"],"award-info":[{"award-number":["201503135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,6,20]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Antimicrobial resistance is found in all microorganisms and has become one of the biggest threats to global health. New antimicrobials with different action mechanisms are effective weapons to fight against antibiotic-resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This review aims to find potential drugs which can be further developed into clinic practice and provide clues for developing more effective antimicrobials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>DNA replication universally exists in all living organisms and is a complicated process in which multiple enzymes are involved in. Enzymes in bacterial DNA replication of initiation and elongation phases bring abundant targets for antimicrobial development as they are conserved and indispensable. In this review, enzyme inhibitors of DNA helicase, DNA primase, topoisomerases, DNA polymerase and DNA ligase were discussed. Special attentions were paid to structures, activities and action modes of these enzyme inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Among these enzymes, type II topoisomerase is the most validated target with abundant inhibitors. For type II topoisomerase inhibitors (excluding quinolones), NBTIs and benzimidazole urea derivatives are the most promising inhibitors because of their good antimicrobial activity and physicochemical properties. Simultaneously, DNA gyrase targeted drugs are particularly attractive in the treatment of tuberculosis as DNA gyrase is the sole type II topoisomerase in Mycobacterium tuberculosis. Relatively, exploitation of antimicrobial inhibitors of the other DNA replication enzymes are primeval, in which inhibitors of topo III are even blank so far.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This review demonstrates that inhibitors of DNA replication enzymes are abundant, diverse and promising, many of which can be developed into antimicrobials to deal with antibioticresistance.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867324666171106160326","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T12:58:34Z","timestamp":1561035514000},"page":"1761-1787","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes"],"prefix":"10.2174","volume":"26","author":[{"given":"Lanhua","family":"Yi","sequence":"first","affiliation":[{"name":"College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi Province 712100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"L\u00fc","sequence":"additional","affiliation":[{"name":"College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi Province 712100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1208\/s12248-015-9722-z","volume":"17","author":"Done H.Y.","year":"2015","unstructured":"Done HY, Venkatesan AK, Halden RU. Does the recent growth of aquaculture create antibiotic resistance threats different from those associated with land animal production in agriculture?","journal-title":"AAPS J"},{"key":"ref=2","first-page":"105","volume":"116","author":"Sabtu N.","year":"2015","unstructured":"Sabtu N, Enoch DA, Brown NM. Antibiotic resistance: what, why, where, when and how?","journal-title":"Br Med Bull"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13756-017-0211-2","volume":"6","author":"Leal J.R.","year":"2017","unstructured":"Leal JR, Conly J, Henderson EA, Manns BJ. How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations.","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrmicro2333","volume":"8","author":"Kohanski M.A.","year":"2010","unstructured":"Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks.","journal-title":"Nat Rev Microbiol"},{"key":"ref=5","volume":"5","author":"O\u2019Donnell M.","year":"2013","unstructured":"O\u2019Donnell M, Langston L, Stillman B. Principles and concepts of DNA replication in bacteria, archaea, and eukarya.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"Aldred K.J.","year":"2014","unstructured":"Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance.","journal-title":"Biochemistry"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/17460441.2012.660478","volume":"7","author":"Sanyal G.","year":"2012","unstructured":"Sanyal G, Doig P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.","journal-title":"Expert Opin Drug Discov"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2006.04.040","volume":"125","author":"Mulcair M.D.","year":"2006","unstructured":"Mulcair MD, Schaeffer PM, Oakley AJ, Cross HF, Neylon C, Hill TM, Dixon NE. A molecular mousetrap determines polarity of termination of DNA replication in E. coli.","journal-title":"Cell"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"23083","DOI":"10.1016\/S0021-9258(18)50059-4","volume":"267","author":"Hwang D.S.","year":"1992","unstructured":"Hwang DS, Kornberg A. Opening of the replication origin of Escherichia coli by DnaA protein with protein HU or IHF.","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.biochem.76.052305.115300","volume":"76","author":"Singleton M.R.","year":"2007","unstructured":"Singleton MR, Dillingham MS, Wigley DB. Structure and mechanism of helicases and nucleic acid translocases.","journal-title":"Annu Rev Biochem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/nar\/gkn999","volume":"37","author":"Lo Y.H.","year":"2009","unstructured":"Lo YH, Tsai KL, Sun YJ, Chen WT, Huang CY, Hsiao CD. The crystal structure of a replicative hexameric helicase DnaC and its complex with single-stranded DNA.","journal-title":"Nucleic Acids Res"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2005.10.110","volume":"16","author":"Dubaele S.","year":"2006","unstructured":"Dubaele S, Jahnke W, Schoepfer J, Fuchs J, Ch\u00e8ne P. Inhibition of DNA helicases with DNA-competitive inhibitors.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.7164\/antibiotics.49.752","volume":"49","author":"Chino M.","year":"1996","unstructured":"Chino M, Nishikawa K, Umekita M, Hayashi C, Yamazaki T, Tsuchida T, Sawa T, Hamada M, Takeuchi T. Heliquinomycin, a new inhibitor of DNA helicase, produced by Streptomyces sp. MJ929-SF2 I. Taxonomy, production, isolation, physico-chemical properties and biological activities.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1016\/j.bmc.2009.05.014","volume":"17","author":"Aiello D.","year":"2009","unstructured":"Aiello D, Barnes MH, Biswas EE, Biswas SB, Gu S, Williams JD, Bowlin TL, Moir DT. Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases.","journal-title":"Bioorg Med Chem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.bmcl.2005.11.076","volume":"16","author":"McKay G.A.","year":"2006","unstructured":"McKay GA, Reddy R, Arhin F, Belley A, Lehoux D, Moeck G, Sarmiento I, Parr TR, Gros P, Pelletier J, Far AR. Triaminotriazine DNA helicase inhibitors with antibacterial activity.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.bmcl.2013.04.055","volume":"23","author":"Li B.","year":"2013","unstructured":"Li B, Pai R, Aiello D, Di M, Barnes MH, Peet NP, Bowlin TL, Moir DT. Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2005.09.002","volume":"26","author":"Cushnie T.P.T.","year":"2005","unstructured":"Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids.","journal-title":"Int J Antimicrob Agents"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10930-010-9302-0","volume":"30","author":"Chen C.C.","year":"2011","unstructured":"Chen CC, Huang CY. Inhibition of Klebsiella pneumoniae DnaB helicase by the flavonol galangin.","journal-title":"Protein J"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1093\/nar\/29.24.5058","volume":"29","author":"Xu H.","year":"2001","unstructured":"Xu H, Ziegelin G, Schr\u00f6der W, Frank J, Ayora S, Alonso JC, Lanka E, Saenger W. Flavones inhibit the hexameric replicative helicase RepA.","journal-title":"Nucleic Acids Res"},{"key":"ref=20","volume":"2012","author":"Lin H.H.","year":"2012","unstructured":"Lin HH, Huang CY. Characterization of flavonol inhibition of DnaB helicase: real-time monitoring, structural modeling, and proposed mechanism.","journal-title":"J Biomed Biotechnol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.bmcl.2004.02.006","volume":"14","author":"Hegde V.R.","year":"2004","unstructured":"Hegde VR, Pu H, Patel M, Black T, Soriano A, Zhao W, Gullo VP, Chan TM. Two new bacterial DNA primase inhibitors from the plant Polygonum cuspidatum.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.chembiol.2005.04.007","volume":"12","author":"Gardiner L.","year":"2005","unstructured":"Gardiner L, Coyle BJ, Chan WC, Soultanas P. Discovery of antagonist peptides against bacterial helicase-primase interaction in B. stearothermophilus by reverse yeast three-hybrid.","journal-title":"Chem Biol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2006.12.043","volume":"128","author":"Wang J.D.","year":"2007","unstructured":"Wang JD, Sanders GM, Grossman AD. Nutritional control of elongation of DNA replication by (p)ppGpp.","journal-title":"Cell"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.plasmid.2009.11.002","volume":"63","author":"Maciag M.","year":"2010","unstructured":"Maciag M, Kochanowska M, Lyze\u0144 R, Wegrzyn G, Szalewska-Pa\u0142asz A. ppGpp inhibits the activity of Escherichia coli DnaG primase.","journal-title":"Plasmid"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1365-2958.2012.08177.x","volume":"85","author":"Kanjee U.","year":"2012","unstructured":"Kanjee U, Ogata K, Houry WA. Direct binding targets of the stringent response alarmone (p)ppGpp.","journal-title":"Mol Microbiol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1021\/np0302302","volume":"66","author":"Chu M.","year":"2003","unstructured":"Chu M, Mierzwa R, Xu L, He L, Terracciano J, Patel M, Gullo V, Black T, Zhao W, Chan TM, McPhail AT. Isolation and structure elucidation of Sch 642305, a novel bacterial DNA primase inhibitor produced by Penicillium verrucosum.","journal-title":"J Nat Prod"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.bmcl.2007.02.056","volume":"17","author":"Agarwal A.","year":"2007","unstructured":"Agarwal A, Louise-May S, Thanassi JA, Podos SD, Cheng J, Thoma C, Liu C, Wiles JA, Nelson DM, Phadke AS, Bradbury BJ, Deshpande MS, Pucci MJ. Small molecule inhibitors of E. coli primase, a novel bacterial target.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks1292","volume":"41","author":"Biswas T.","year":"2013","unstructured":"Biswas T, Resto-Rold\u00e1n E, Sawyer SK, Artsimovitch I, Tsodikov OV. A novel non-radioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG.","journal-title":"Nucleic Acids Res"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ja.2014.131","volume":"68","author":"Gajadeera C.","year":"2015","unstructured":"Gajadeera C, Willby MJ, Green KD, Shaul P, Fridman M, Garneau-Tsodikova S, Posey JE, Tsodikov OV. Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1021\/bi4011286","volume":"52","author":"Biswas T.","year":"2013","unstructured":"Biswas T, Green KD, Garneau-Tsodikova S, Tsodikov OV. Discovery of inhibitors of Bacillus anthracis primase DnaG.","journal-title":"Biochemistry"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/jac\/dkl556","volume":"59","author":"Cheng B.","year":"2007","unstructured":"Cheng B, Liu IF, Tse-Dinh YC. Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I.","journal-title":"J Antimicrob Chemother"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"10387","DOI":"10.1093\/nar\/gkv041","volume":"43","author":"Yamaguchi Y.","year":"2015","unstructured":"Yamaguchi Y, Inouye M. An endogenous protein inhibitor, YjhX (TopAI), for topoisomerase I from Escherichia coli.","journal-title":"Nucleic Acids Res"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/JB.181.10.3185-3192.1999","volume":"181","author":"Yigit H.","year":"1999","unstructured":"Yigit H, Reznikoff WS. Escherichia coli DNA topoisomerase I copurifies with Tn5 transposase, and Tn5 transposase inhibits topoisomerase I.","journal-title":"J Bacteriol"},{"key":"ref=34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124309","volume":"10","author":"Mattenberger Y.","year":"2015","unstructured":"Mattenberger Y, Silva F, Belin D. 55.2, a phage T4 ORFan gene, encodes an inhibitor of Escherichia coli topoisomerase I and increases phage fitness.","journal-title":"PLoS One"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-4658.2011.08398.x","volume":"279","author":"Leelaram M.N.","year":"2012","unstructured":"Leelaram MN, Bhat AG, Hegde SM, Manjunath R, Nagaraja V. Inhibition of type IA topoisomerase by a monoclonal antibody through perturbation of DNA cleavage-religation equilibrium.","journal-title":"FEBS J"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/bj2850503","volume":"285","author":"Mizushima T.","year":"1992","unstructured":"Mizushima T, Natori S, Sekimizu K. Inhibition of Escherichia coli DNA topoisomerase I activity by phospholipids.","journal-title":"Biochem J"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/AAC.00163-13","volume":"57","author":"Shapiro A.B.","year":"2013","unstructured":"Shapiro AB, Newman J, Goteti K, Beaudoin ME, Harrison R, Hopkins S, Agrawal N, Rivin O. Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.31.12.1925","volume":"31","author":"Tabary X.","year":"1987","unstructured":"Tabary X, Moreau N, Dureuil C, Le Goffic F. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.34.10.1955","volume":"34","author":"Moreau N.J.","year":"1990","unstructured":"Moreau NJ, Robaux H, Baron L, Tabary X. Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijantimicag.2009.07.018","volume":"35","author":"Bansal S.","year":"2010","unstructured":"Bansal S, Tawar U, Singh M, Nikravesh A, Good L, Tandon V. Old class but new dimethoxy analogue of benzimidazole: a bacterial topoisomerase I inhibitor.","journal-title":"Int J Antimicrob Agents"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/jac\/dks322","volume":"67","author":"Bansal S.","year":"2012","unstructured":"Bansal S, Sinha D, Singh M, Cheng B, Tse-Dinh YC, Tandon V. 3,4-dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I.","journal-title":"J Antimicrob Chemother"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1039\/C4MD00140K","volume":"5","author":"Ranjan N.","year":"2014","unstructured":"Ranjan N, Fulcrand G, King A, Brown J, Jiang X, Leng F, Arya DP. Selective inhibition of bacterial topoisomerase I by alkynyl-bisbenzimidazoles.","journal-title":"MedChemComm"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.04516-14","volume":"59","author":"Godbole A.A.","year":"2015","unstructured":"Godbole AA, Ahmed W, Bhat RS, Bradley EK, Ekins S, Nagaraja V. Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0969-2126(00)80027-1","volume":"7","author":"Mondrag\u00f3n A.","year":"1999","unstructured":"Mondrag\u00f3n A, DiGate R. The structure of Escherichia coli DNA topoisomerase III.","journal-title":"Structure"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/35082615","volume":"411","author":"Changela A.","year":"2001","unstructured":"Changela A, DiGate RJ, Mondrag\u00f3n A. Crystal structure of a complex of a type IA DNA topoisomerase with a single-stranded DNA molecule.","journal-title":"Nature"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nsmb.2775","volume":"21","author":"Bocquet N.","year":"2014","unstructured":"Bocquet N, Bizard AH, Abdulrahman W, Larsen NB, Faty M, Cavadini S, Bunker RD, Kowalczykowski SC, Cejka P, Hickson ID, Thom\u00e4 NH. Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase III\u03b1 and RMI1.","journal-title":"Nat Struct Mol Biol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","volume":"92","author":"Collin F.","year":"2011","unstructured":"Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0966-842X(98)01311-0","volume":"6","author":"Couturier M.","year":"1998","unstructured":"Couturier M. Bahassi el-M,Van Melderen, L. Bacterial death by DNA gyrase poisoning.","journal-title":"Trends Microbiol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dkv161","volume":"70","author":"Chiriac A.I.","year":"2015","unstructured":"Chiriac AI, Kloss F, Kr\u00e4mer J, Vuong C, Hertweck C, Sahl H-G. Mode of action of closthioamide: the first member of the polythioamide class of bacterial DNA gyrase inhibitors.","journal-title":"J Antimicrob Chemother"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1016\/j.bmc.2015.08.004","volume":"23","author":"Werner M.M.","year":"2015","unstructured":"Werner MM, Patel BA, Talele TT, Ashby CR, Li Z, Zauhar RJ. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.","journal-title":"Bioorg Med Chem"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","volume":"41","author":"Schoeffler A.J.","year":"2008","unstructured":"Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology.","journal-title":"Q Rev Biophys"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1086\/428051","volume":"41","author":"Andriole V.T.","year":"2005","unstructured":"Andriole VT. The quinolones: past, present, and future.","journal-title":"Clin Infect Dis"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"Bax B.D.","year":"2010","unstructured":"Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. Type IIA topoisomerase inhibition by a new class of antibacterial agents.","journal-title":"Nature"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nsmb.1604","volume":"16","author":"Laponogov I.","year":"2009","unstructured":"Laponogov I, Sohi MK, Veselkov DA, Pan X-S, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.","journal-title":"Nat Struct Mol Biol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nsmb.1892","volume":"17","author":"Wohlkonig A.","year":"2010","unstructured":"Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.","journal-title":"Nat Struct Mol Biol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1093\/nar\/gkt124","volume":"41","author":"Aldred K.J.","year":"2013","unstructured":"Aldred KJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.","journal-title":"Nucleic Acids Res"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","volume":"289","author":"Mustaev A.","year":"2014","unstructured":"Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, Hiasa H, Marks KR, Kerns RJ, Berger JM, Drlica K. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.","journal-title":"J Biol Chem"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/med.21434","volume":"37","author":"Bachurin S.O.","year":"2017","unstructured":"Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer\u2019s Disease: the major trends.","journal-title":"Med Res Rev"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.bmcl.2013.07.013","volume":"23","author":"Miles T.J.","year":"2013","unstructured":"Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Huang J, Jones GE, Sukmar SKK, Spitzfaden C, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.bmcl.2007.03.004","volume":"17","author":"Wiener J.J.M.","year":"2007","unstructured":"Wiener JJM, Gomez L, Venkatesan H, Santill\u00e1n A, Allison BD, Schwarz KL, Shinde S, Tang L, Hack MD, Morrow BJ, Motley ST, Goldschmidt RM, Shaw KJ, Jones TK, Grice CA. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1021\/jm2008826","volume":"54","author":"Reck F.","year":"2011","unstructured":"Reck F, Alm R, Brassil P, Newman J, Dejonge B, Eyermann CJ, Breault G, Breen J, Comita-Prevoir J, Cronin M, Davis H, Ehmann D, Galullo V, Geng B, Grebe T, Morningstar M, Walker P, Hayter B, Fisher S. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.","journal-title":"J Med Chem"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.00496-08","volume":"52","author":"Black M.T.","year":"2008","unstructured":"Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1021\/jm500432n","volume":"57","author":"Hameed P.","year":"2014","unstructured":"Hameed P. S.; Patil, V.; Solapure, S.; Sharma, U.; Madhavapeddi, P.; Raichurkar, A.; Chinnapattu, M.; Manjrekar, P.; Shanbhag, G.; Puttur, J.; Shinde, V.; Menasinakai, S.; Rudrapatana, S.; Achar, V.; Awasthy, D.; Nandishaiah, R.; Humnabadkar, V.; Ghosh, A.; Narayan, C.; Ramya, V.K.; Kaur, P.; Sharma, S.; Werngren, J.; Hoffner, S.; Panduga, V.; Kumar, C.N.N.; Reddy, J.; Kumar K N, M.; Ganguly, S.; Bharath, S.; Bheemarao, U.; Mukherjee, K.; Arora, U.; Gaonkar, S.; Coulson, M.; Waterson, D.; Sambandamurthy, V.K.; de Sousa, S.M. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.","journal-title":"J Med Chem"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/ml500069w","volume":"5","author":"Singh S.B.","year":"2014","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen D, Lagrutta A, Bradley P, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Wei C, Fukuda H, Kishii R, Takei M, Fukuda Y. Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents.","journal-title":"ACS Med Chem Lett"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1128\/AAC.02778-13","volume":"58","author":"Dougherty T.J.","year":"2014","unstructured":"Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm300690s","volume":"55","author":"Reck F.","year":"2012","unstructured":"Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1128\/AAC.00619-16","volume":"60","author":"Tan C.M.","year":"2016","unstructured":"Tan CM, Gill CJ, Wu J, Toussaint N, Yin J, Tsuchiya T, Garlisi CG, Kaelin D, Meinke PT, Miesel L, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Oohata K, Takeuchi T, Shibue T, Takano H, Nishimura A, Fukuda Y, Singh SB. In vitro and in vivo characterization of the novel oxabicyclooctane-linked bacterial topoisomerase inhibitor AM-8722, a selective, potent inhibitor of bacterial DNA Gyrase.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.bmcl.2015.03.044","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Sherer E, Joyce LA, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takano H, Shibasaki M, Yajima M, Nishimura A, Shibata T, Fukuda Y. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.bmcl.2015.04.063","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Gill C, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takeuchi T, Shibue T, Ohata K, Takano H, Ban S, Nishimura A, Fukuda Y. Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.bmcl.2015.04.002","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Ohata K, Takano H, Kurasaki H, Takeuchi T, Nishimura A, Fukuda Y. Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1016\/j.bmcl.2015.06.061","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Meinke PT, Wu J, Miesel L, Tan CM, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Takeuchi T, Takano H, Ohata K, Kurasaki H, Nishimura A, Shibata T, Fukuda Y. Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.bmcl.2015.06.057","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Liao Y, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Yajima M, Shibue T, Shibata T, Ohata K, Nishimura A, Fukuda Y. Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1039\/C5MD00297D","volume":"6","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei CQ, Liao YG, Peng XJ, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Takeuchi T, Ohata K, Nishimura A, Fukuda Y. C1-C2-linker substituted 1,5-naphthyridine analogues of oxabicyclooctane-linked NBTIs as broad-spectrum antibacterial agents (part 7).","journal-title":"MedChemComm"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1128\/JCM.00656-14","volume":"52","author":"Ross J.E.","year":"2014","unstructured":"Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN. Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.","journal-title":"J Clin Microbiol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"e02047","DOI":"10.1128\/AAC.02047-16","volume":"61","author":"Farrell D.J.","year":"2017","unstructured":"Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=76","first-page":"e02095","volume":"61","author":"O\u2019Riordan W.","year":"2017","unstructured":"O\u2019Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.49.3.1093-1100.2005","volume":"49","author":"Flatman R.H.","year":"2005","unstructured":"Flatman RH, Howells AJ, Heide L, Fiedler HP, Maxwell A. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.1179123","volume":"326","author":"Edwards M.J.","year":"2009","unstructured":"Edwards MJ, Flatman RH, Mitchenall LA, Stevenson CEM, Le TBK, Clarke TA, McKay AR, Fiedler H-P, Buttner MJ, Lawson DM, Maxwell A. A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase.","journal-title":"Science"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF00273616","volume":"226","author":"Bernard P.","year":"1991","unstructured":"Bernard P, Couturier M. The 41 carboxy-terminal residues of the miniF plasmid CcdA protein are sufficient to antagonize the killer activity of the CcdB protein.","journal-title":"Mol Gen Genet"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1093\/nar\/gkl636","volume":"34","author":"Smith A.B.","year":"2006","unstructured":"Smith AB, Maxwell A. A strand-passage conformation of DNA gyrase is required to allow the bacterial toxin, CcdB, to access its binding site.","journal-title":"Nucleic Acids Res"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1006\/jmbi.1997.1357","volume":"273","author":"Critchlow S.E.","year":"1997","unstructured":"Critchlow SE, O\u2019Dea MH, Howells AJ, Couturier M, Gellert M, Maxwell A. The interaction of the F plasmid killer protein, CcdB, with DNA gyrase: induction of DNA cleavage and blocking of transcription.","journal-title":"J Mol Biol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/jmbi.1996.0102","volume":"256","author":"Maki S.","year":"1996","unstructured":"Maki S, Takiguchi S, Horiuchi T, Sekimizu K, Miki T. Partner switching mechanisms in inactivation and rejuvenation of Escherichia coli DNA gyrase by F plasmid proteins LetD (CcdB) and LetA (CcdA).","journal-title":"J Mol Biol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1006\/jmbi.1998.2395","volume":"285","author":"Loris R.","year":"1999","unstructured":"Loris R, Dao-Thi MH, Bahassi EM, Van Melderen L, Poortmans F, Liddington R, Couturier M, Wyns L. Crystal structure of CcdB, a topoisomerase poison from E. coli.","journal-title":"J Mol Biol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0022-2836(92)90629-X","volume":"226","author":"Bernard P.","year":"1992","unstructured":"Bernard P, Couturier M. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes.","journal-title":"J Mol Biol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jmb.2005.03.049","volume":"348","author":"Dao-Thi M.H.","year":"2005","unstructured":"Dao-Thi MH, Van Melderen L, De Genst E, Afif H, Buts L, Wyns L, Loris R. Molecular basis of gyrase poisoning by the addiction toxin CcdB.","journal-title":"J Mol Biol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1016\/j.bmcl.2008.10.008","volume":"18","author":"Trovatti E.","year":"2008","unstructured":"Trovatti E, Cotrim CA, Garrido SS, Barros RS, Marchetto R. Peptides based on CcdB protein as novel inhibitors of bacterial topoisomerases.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2958.2002.02921.x","volume":"44","author":"Jiang Y.","year":"2002","unstructured":"Jiang Y, Pogliano J, Helinski DR, Konieczny I. ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase.","journal-title":"Mol Microbiol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejmech.2012.06.008","volume":"54","author":"Barbosa L.C.","year":"2012","unstructured":"Barbosa LC, Garrido SS, Garcia A, Delfino DB. Santos, Ldo.N.; Marchetto, R. Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases.","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/JB.01185-10","volume":"193","author":"Yuan J.","year":"2011","unstructured":"Yuan J, Yamaichi Y, Waldor MK. The three vibrio cholerae chromosome II-encoded ParE toxins degrade chromosome I following loss of chromosome II.","journal-title":"J Bacteriol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"40397","DOI":"10.1074\/jbc.M110.138776","volume":"285","author":"Yuan J.","year":"2010","unstructured":"Yuan J, Sterckx Y, Mitchenall LA, Maxwell A, Loris R, Waldor MK. Vibrio cholerae ParE2 poisons DNA gyrase via a mechanism distinct from other gyrase inhibitors.","journal-title":"J Biol Chem"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1093\/nar\/gki622","volume":"33","author":"Manjunatha U.H.","year":"2005","unstructured":"Manjunatha UH, Maxwell A, Nagaraja V. A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.","journal-title":"Nucleic Acids Res"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1074\/jbc.275.13.9468","volume":"275","author":"Brino L.","year":"2000","unstructured":"Brino L, Urzhumtsev A, Mousli M, Bronner C, Mitschler A, Oudet P, Moras D. Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center.","journal-title":"J Biol Chem"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.48.5.1856-1864.2004","volume":"48","author":"Bellon S.","year":"2004","unstructured":"Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/092986707781368414","volume":"14","author":"Oblak M.","year":"2007","unstructured":"Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents.","journal-title":"Curr Med Chem"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/bi970294+","volume":"36","author":"Holdgate G.A.","year":"1997","unstructured":"Holdgate GA, Tunnicliffe A, Ward WHJ, Weston SA, Rosenbrock G, Barth PT, Taylor IWF, Pauptit RA, Timms D. The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study.","journal-title":"Biochemistry"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1097-0134(199705)28:1<41::AID-PROT4>3.0.CO;2-M","volume":"28","author":"Tsai F.T.F.","year":"1997","unstructured":"Tsai FTF, Singh OMP, Skarzynski T, Wonacott AJ, Weston S, Tucker A, Pauptit RA, Breeze AL, Poyser JP, O\u2019Brien R, Ladbury JE, Wigley DB. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin.","journal-title":"Proteins"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1021\/bi0159837","volume":"41","author":"Lafitte D.","year":"2002","unstructured":"Lafitte D, Lamour V, Tsvetkov PO, Makarov AA, Klich M, Deprez P, Moras D, Briand C, Gilli R. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5\u2032-methyl group of the noviose.","journal-title":"Biochemistry"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0960-894X(00)00304-8","volume":"10","author":"Musicki B.","year":"2000","unstructured":"Musicki B, Periers AM, Laurin P, Ferroud D, Benedetti Y, Lachaud S, Chatreaux F, Haesslein JL, Iltis A, Pierre C, Khider J, Tessot N, Airault M, Demassey J, Dupuis-Hamelin C, Lassaigne P, Bonnefoy A, Vicat P, Klich M. Improved antibacterial activities of coumarin antibiotics bearing 5\u2032,5\u2032-dialkylnoviose: biological activity of RU79115.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7164\/antibiotics.47.37","volume":"47","author":"Kamiyama T.","year":"1994","unstructured":"Kamiyama T, Shimma N, Ohtsuka T, Nakayama N, Itezono Y, Nakada N, Watanabe J, Yokose K. Cyclothialidine, a novel DNA gyrase inhibitor. II. Isolation, characterization and structure elucidation.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/j.1460-2075.1996.tb00483.x","volume":"15","author":"Lewis R.J.","year":"1996","unstructured":"Lewis RJ, Singh OMP, Smith CV, Skarzynski T, Maxwell A, Wonacott AJ, Wigley DB. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography.","journal-title":"EMBO J"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0163-7258(93)90017-8","volume":"60","author":"Goetschi E.","year":"1993","unstructured":"Goetschi E, Angehrn P, Gmuender H, Hebeisen P, Link H, Masciadri R, Nielsen J. Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors.","journal-title":"Pharmacol Ther"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/jm0310232","volume":"47","author":"Angehrn P.","year":"2004","unstructured":"Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP. New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.","journal-title":"J Med Chem"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/jm0010623","volume":"44","author":"Rudolph J.","year":"2001","unstructured":"Rudolph J, Theis H, Hanke R, Endermann R, Johannsen L, Geschke F. seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties.","journal-title":"J Med Chem"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1021\/jm1014023","volume":"54","author":"Angehrn P.","year":"2011","unstructured":"Angehrn P, Goetschi E, Gmuender H, Hebeisen P, Hennig M, Kuhn B, Luebbers T, Reindl P, Ricklin F, Schmitt-Hoffmann A. A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.","journal-title":"J Med Chem"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"Article No.: 23634","DOI":"10.1038\/srep23634","volume":"6","author":"Fang Y.","year":"2016","unstructured":"Fang Y, Lu Y, Zang X, Wu T, Qi X, Pan S, Xu X. 3D-QSAR and docking studies of flavonoids as potent Escherichia coli inhibitors.","journal-title":"Scientific Reports"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0006-291X(03)01006-4","volume":"306","author":"Plaper A.","year":"2003","unstructured":"Plaper A, Golob M, Hafner I, Oblak M, Solmajer T, Jerala R. Characterization of quercetin binding site on DNA gyrase.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=107","first-page":"8587","volume":"18","author":"Suriyanarayanan B.","year":"2013","unstructured":"Suriyanarayanan B, Shanmugam K, Santhosh RS. Synthetic quercetin inhibits mycobacterial growth possibly by interacting with DNA gyrase.","journal-title":"Rom Biotechnol Lett"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1021\/jm200010x","volume":"54","author":"Hossion A.M.L.","year":"2011","unstructured":"Hossion AML, Zamami Y, Kandahary RK, Tsuchiya T, Ogawa W, Iwado A, Sasaki K. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.","journal-title":"J Med Chem"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chembiol.2011.06.011","volume":"18","author":"Phillips J.W.","year":"2011","unstructured":"Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Mart\u00edn J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RGK, Singh SB. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.","journal-title":"Chem Biol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1021\/cb5001197","volume":"9","author":"Lu J.","year":"2014","unstructured":"Lu J, Patel S, Sharma N, Soisson SM, Kishii R, Takei M, Fukuda Y, Lumb KJ, Singh SB. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode.","journal-title":"ACS Chem Biol"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/AAC.00382-15","volume":"59","author":"Singh S.B.","year":"2015","unstructured":"Singh SB, Dayananth P, Balibar CJ, Garlisi CG, Lu J, Kishii R, Takei M, Fukuda Y, Ha S, Young K. Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.bmcl.2012.09.071","volume":"22","author":"Singh S.B.","year":"2012","unstructured":"Singh SB, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, de la Cruz M, Mart\u00edn J, Vicente F, Genilloud O, Donald RG, Phillips JW. Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tibs.2014.01.001","volume":"39","author":"Garcia-Pino A.","year":"2014","unstructured":"Garcia-Pino A, Zenkin N, Loris R. The many faces of Fic: structural and functional aspects of Fic enzymes.","journal-title":"Trends Biochem Sci"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.celrep.2015.07.056","volume":"12","author":"Harms A.","year":"2015","unstructured":"Harms A, Stanger FV, Scheu PD, de Jong IG, Goepfert A, Glatter T, Gerdes K, Schirmer T, Dehio C. Adenylylation of Gyrase and Topo IV by FicT Toxins Disrupts Bacterial DNA Topology.","journal-title":"Cell Rep"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"ra11","DOI":"10.1126\/scisignal.aad0446","volume":"9","author":"Lu C.","year":"2016","unstructured":"Lu C, Nakayasu ES, Zhang L-Q, Luo Z-Q. Identification of Fic-1 as an enzyme that inhibits bacterial DNA replication by AMPylating GyrB, promoting filament formation.","journal-title":"Sci Signal"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/14756366.2014.1003214","volume":"31","author":"Paneth A.","year":"2016","unstructured":"Paneth A, St\u0105czek P, Plech T, Strzelczyk A, Dzitko K, Wujec M, Ku\u015bmierz E, Kosikowska U, Grzegorczyk A, Paneth P. Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cmdc.201500556","volume":"11","author":"Jeankumar V.U.","year":"2016","unstructured":"Jeankumar VU, Saxena S, Vats R, Reshma RS, Janupally R, Kulkarni P, Yogeeswari P, Sriram D. Structure-guided discovery of antitubercular agents that target the gyrase ATPase domain.","journal-title":"ChemMedChem"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.5b00489","volume":"58","author":"Toma\u0161i\u010d T.","year":"2015","unstructured":"Toma\u0161i\u010d T, Katsamakas S, Hodnik \u017d, Ila\u0161 J, Brvar M, Solmajer T, Montalv\u00e3o S, Tammela P, Banjanac M, Ergovi\u0107 G, Anderluh M, Peterlin Ma\u0161i\u010d L, Kikelj D. Discovery of 4,5,6,7-Tetrahydrobenzo [,2-d]thiazoles as novel DNA gyrase inhibitors targeting the ATP-binding Site.","journal-title":"J Med Chem"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2013.09.025","volume":"70","author":"Jeankumar V.U.","year":"2013","unstructured":"Jeankumar VU, Renuka J, Santosh P, Soni V, Sridevi JP, Suryadevara P, Yogeeswari P, Sriram D. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.","journal-title":"Eur J Med Chem"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.bmc.2012.02.052","volume":"20","author":"Brvar M.","year":"2012","unstructured":"Brvar M, Perdih A, Hodnik V, Renko M, Anderluh G, Jerala R, Solmajer T. In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.","journal-title":"Bioorg Med Chem"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1016\/j.bmc.2004.08.010","volume":"12","author":"Tanitame A.","year":"2004","unstructured":"Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Suzuki K, Ueda T, Terauchi H, Kawasaki M, Nagai K, Wachi M, Yamagishi J. Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring.","journal-title":"Bioorg Med Chem"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1016\/j.bmcl.2004.03.044","volume":"14","author":"Tanitame A.","year":"2004","unstructured":"Tanitame A, Oyamada Y, Ofuji K, Kyoya Y, Suzuki K, Ito H, Kawasaki M, Nagai K, Wachi M, Yamagishi J. Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bmc.2014.12.001","volume":"23","author":"Jeankumar V.U.","year":"2015","unstructured":"Jeankumar VU, Kotagiri S, Janupally R, Suryadevara P, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.","journal-title":"Bioorg Med Chem"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1021\/jm030394f","volume":"47","author":"Tanitame A.","year":"2004","unstructured":"Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Iwai N, Hiyama Y, Suzuki K, Ito H, Terauchi H, Kawasaki M, Nagai K, Wachi M, Yamagishi J. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.","journal-title":"J Med Chem"},{"key":"ref=125","unstructured":"Triazine derivatives and their use as antibacterial agents U.S. Patent, WO1999001442A1, Jan 14, 1999."},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1016\/j.bmcl.2011.10.010","volume":"21","author":"Sherer B.A.","year":"2011","unstructured":"Sherer BA, Hull K, Green O, Basarab G, Hauck S, Hill P, Loch JT, Mullen G, Bist S, Bryant J, Boriack-Sjodin A, Read J, DeGrace N, Uria-Nickelsen M, Illingworth RN, Eakin AE. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1021\/jm401268f","volume":"56","author":"Kale M.G.","year":"2013","unstructured":"Kale MG, Raichurkar A. P, S.H.; Waterson, D.; McKinney, D.; Manjunatha, M.R.; Kranthi, U.; Koushik, K.; Jena, Lk.; Shinde, V.; Rudrapatna, S.; Barde, S.; Humnabadkar, V.; Madhavapeddi, P.; Basavarajappa, H.; Ghosh, A.; Ramya, V.K.; Guptha, S.; Sharma, S.; Vachaspati, P.; Kumar, K.N.M.; Giridhar, J.; Reddy, J.; Panduga, V.; Ganguly, S.; Ahuja, V.; Gaonkar, S.; Kumar, C.N.N.; Ogg, D.; Tucker, J.A.; Boriack-Sjodin, P.A.; de Sousa, S.M.; Sambandamurthy, V.K.; Ghorpade, S.R. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.","journal-title":"J Med Chem"},{"key":"ref=128","unstructured":"Heterocyclic urea derivatives for the treatment of bacterial infections U.S. Patent, WO2009147433A1, Dec 10, 2009"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1016\/j.bmcl.2009.07.141","volume":"19","author":"Starr J.T.","year":"2009","unstructured":"Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H, Gage JW, Lockard M, Rauckhorst MR, Owen RM, Lall MS, Tomilo M, Chen H, McCurdy SP, Barbachyn MR. 5-(2-Pyrimidinyl)-imidazo [,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=130","unstructured":"Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents U.S. Patent, WO2009GB50609, Dec 10, 2009."},{"key":"ref=131","unstructured":"Benzothiazoles and aza-analogues thereof use as antibacterial agents U.S, WO2009156966A1, Dec 30;2009"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm800318d","volume":"51","author":"Charifson P.S.","year":"2008","unstructured":"Charifson PS, Grillot A-L, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian S-K, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.","journal-title":"J Med Chem"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.bmcl.2012.11.032","volume":"23","author":"Tari L.W.","year":"2013","unstructured":"Tari LW, Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Nix J, Finn J. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=134","volume":"8","author":"Tari L.W.","year":"2013","unstructured":"Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J. Tricyclic GyrB\/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.","journal-title":"PLoS One"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1021\/jm500563g","volume":"57","author":"Grillot A.L.","year":"2014","unstructured":"Grillot AL, Le Tiran A, Shannon D, Krueger E, Liao Y, O\u2019Dowd H, Tang Q, Ronkin S, Wang T, Waal N, Li P, Lauffer D, Sizensky E, Tanoury J, Perola E, Grossman TH, Doyle T, Hanzelka B, Jones S, Dixit V, Ewing N, Liao S, Boucher B, Jacobs M, Bennani Y, Charifson PS. Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.","journal-title":"J Med Chem"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm800318d","volume":"51","author":"Charifson P.S.","year":"2008","unstructured":"Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.","journal-title":"J Med Chem"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/acsmedchemlett.5b00196","volume":"6","author":"O\u2019Dowd H.","year":"2015","unstructured":"O\u2019Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O\u2019Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL. Discovery and characterization of a water-soluble prodrug of a dual inhibitor of bacterial DNA gyrase and topoisomerase IV.","journal-title":"ACS Med Chem Lett"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev.bi.64.070195.001131","volume":"64","author":"Kelman Z.","year":"1995","unstructured":"Kelman Z, O\u2019Donnell M. DNA polymerase III holoenzyme: structure and function of a chromosomal replicating machine.","journal-title":"Annu Rev Biochem"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"21398","DOI":"10.1074\/jbc.271.35.21398","volume":"271","author":"Tougu K.","year":"1996","unstructured":"Tougu K, Marians KJ. The interaction between helicase and primase sets the replication fork clock.","journal-title":"J Biol Chem"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1128\/AAC.44.8.2217-2221.2000","volume":"44","author":"Daly J.S.","year":"2000","unstructured":"Daly JS, Giehl TJ, Brown NC, Zhi C, Wright GE, Ellison RT. In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1073\/pnas.71.8.2973","volume":"71","author":"Low R.L.","year":"1974","unstructured":"Low RL, Rashbaum SA, Cozzarelli NR. Mechanism of inhibition of Bacillus subtilis DNA polymerase 3 by the arylhydrazinopyrimidine antimicrobial agents.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1073\/pnas.70.2.512","volume":"70","author":"Mackenzie J.M.","year":"1973","unstructured":"Mackenzie JM, Neville MM, Wright GE, Brown NC. Hydroxyphenylazopyrimidines: characterization of the active forms and their inhibitory action on a DNA polymerase from Bacillus subtilis.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1021\/jm050517r","volume":"48","author":"Zhi C.","year":"2005","unstructured":"Zhi C, Long ZY, Manikowski A, Brown NC, Tarantino PM, Holm K, Dix EJ, Wright GE, Foster KA, Butler MM, LaMarr WA, Skow DJ, Motorina I, Lamothe S, Storer R. Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils.","journal-title":"J Med Chem"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.43.8.1982","volume":"43","author":"Tarantino P.M.","year":"1999","unstructured":"Tarantino PM, Zhi C, Wright GE, Brown NC. Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bmcl.2005.11.009","volume":"16","author":"Rose Y.","year":"2006","unstructured":"Rose Y, Ciblat S, Reddy R, Belley AC, Dietrich E, Lehoux D, McKay GA, Poirier H, Far AR, Delorme D. Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1016\/j.bmcl.2011.05.093","volume":"21","author":"Xu W.C.","year":"2011","unstructured":"Xu WC, Wright GE, Brown NC, Long ZY, Zhi CX, Dvoskin S, Gambino JJ, Barnes MH, Butler MM. 7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/jm0510023","volume":"49","author":"Zhi C.","year":"2006","unstructured":"Zhi C, Long ZY, Manikowski A, Comstock J, Xu WC, Brown NC, Tarantino PM, Holm KA, Dix EJ, Wright GE, Barnes MH, Butler MM, Foster KA, LaMarr WA, Bachand B, Bethell R, Cadilhac C, Charron S, Lamothe S, Motorina I, Storer R. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.","journal-title":"J Med Chem"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/AAC.01311-05","volume":"51","author":"Butler M.M.","year":"2007","unstructured":"Butler MM, Lamarr WA, Foster KA, Barnes MH, Skow DJ, Lyden PT, Kustigian LM, Zhi C, Brown NC, Wright GE, Bowlin TL. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=149","unstructured":"Antibacterial pyrazole carboxylic acid hydrazides U.S. Patent, WO2004094370, Nov 4, 2004."},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bmcl.2008.12.038","volume":"19","author":"Guiles J.","year":"2009","unstructured":"Guiles J, Sun X, Critchley IA, Ochsner U, Tregay M, Stone K, Bertino J, Green L, Sabin R, Dean F, Dallmann HG, McHenry CS, Janjic N. Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/187152612804142279","volume":"12","author":"Barnes M.H.","year":"2012","unstructured":"Barnes MH, Butler MM, Wright GE, Brown NC. Antimicrobials targeted to the replication-specific DNA polymerases of gram-positive bacteria: target potential of dnaE.","journal-title":"Infect Disord Drug Targets"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.chembiol.2015.08.015","volume":"22","author":"Painter R.E.","year":"2015","unstructured":"Painter RE, Adam GC, Arocho M, DiNunzio E, Donald RGK, Dorso K, Genilloud O, Gill C, Goetz M, Hairston NN, Murgolo N, Nare B, Olsen DB, Powles M, Racine F, Su J, Vicente F, Wisniewski D, Xiao L, Hammond M, Young K. Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin.","journal-title":"Chem Biol"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/med.20114","volume":"28","author":"Dwivedi N.","year":"2008","unstructured":"Dwivedi N, Dube D, Pandey J, Singh B, Kukshal V, Ramachandran R, Tripathi RP. NAD(+)-dependent DNA ligase: a novel target waiting for the right inhibitor.","journal-title":"Med Res Rev"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1093\/nar\/gki1006","volume":"33","author":"Srivastava S.K.","year":"2005","unstructured":"Srivastava SK, Dube D, Tewari N, Dwivedi N, Tripathi RP, Ramachandran R. Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I.","journal-title":"Nucleic Acids Res"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1016\/j.bmcl.2012.04.037","volume":"22","author":"Gu W.","year":"2012","unstructured":"Gu W, Wang T, Maltais F, Ledford B, Kennedy J, Wei Y, Gross CH, Parsons J, Duncan L, Arends SJR, Moody C, Perola E, Green J, Charifson PS. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"30273","DOI":"10.1074\/jbc.M503780200","volume":"280","author":"Srivastava S.K.","year":"2005","unstructured":"Srivastava SK, Tripathi RP, Ramachandran R. NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis. Crystal structure of the adenylation domain and identification of novel inhibitors.","journal-title":"J Biol Chem"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"39435","DOI":"10.1074\/jbc.M306479200","volume":"278","author":"Br\u00f6tz-Oesterhelt H.","year":"2003","unstructured":"Br\u00f6tz-Oesterhelt H, Knezevic I, Bartel S, Lampe T, Warnecke-Eberz U, Ziegelbauer K, H\u00e4bich D, Labischinski H. Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones.","journal-title":"J Biol Chem"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/prot.21457","volume":"69","author":"Srivastava S.K.","year":"2007","unstructured":"Srivastava SK, Dube D, Kukshal V, Jha AK, Hajela K, Ramachandran R. NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor.","journal-title":"Proteins"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1111\/j.1742-4658.2008.06652.x","volume":"275","author":"Meier T.I.","year":"2008","unstructured":"Meier TI, Yan D, Peery RB, McAllister KA, Zook C, Peng SB, Zhao G. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases.","journal-title":"FEBS J"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1039\/c2md00168c","volume":"3","author":"Kukshal V.","year":"2012","unstructured":"Kukshal V, Mishra M, Ajay A, Khanam T, Sharma R, Dube D, Chopra D, Tripathi RP, Ramachandran R. Synthesis and bioevaluation of aryl hydroxamates distinguishing between NAD(+) and ATP-dependent DNA ligases.","journal-title":"MedChemComm"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ab.2007.03.028","volume":"366","author":"Miesel L.","year":"2007","unstructured":"Miesel L, Kravec C, Xin ATP, McMonagle P, Ma S, Pichardo J, Feld B, Barrabee E, Palermo R. A high-throughput assay for the adenylation reaction of bacterial DNA ligase.","journal-title":"Anal Biochem"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.01181-10","volume":"55","author":"Mills S.D.","year":"2011","unstructured":"Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS, Novel Bacterial NAD. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bcp.2012.06.017","volume":"84","author":"Jahi\u0107 H.","year":"2012","unstructured":"Jahi\u0107 H, Liu CF, Thresher J, Livchak S, Wang H, Ehmann DE. The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds.","journal-title":"Biochem Pharmacol"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1016\/j.bmcl.2011.05.128","volume":"21","author":"Stokes S.S.","year":"2011","unstructured":"Stokes SS, Huynh H, Gowravaram M, Albert R, Cavero-Tomas M, Chen B, Harang J, Loch JT, Lu M, Mullen GB, Zhao S, Liu C-F, Mills SD. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bmcl.2011.11.071","volume":"22","author":"Stokes S.S.","year":"2012","unstructured":"Stokes SS, Gowravaram M, Huynh H, Lu M, Mullen GB, Chen B, Albert R, O\u2019Shea TJ, Rooney MT, Hu H, Newman JV, Mills SD. Discovery of bacterial NAD-dependent DNA ligase inhibitors: improvements in clearance of adenosine series.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bmcl.2013.11.007","volume":"24","author":"Murphy-Benenato K.","year":"2014","unstructured":"Murphy-Benenato K, Wang H, McGuire HM, Davis HE, Gao N, Prince DB, Jahic H, Stokes SS, Boriack-Sjodin PA. Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.bmcl.2012.04.038","volume":"22","author":"Wang T.","year":"2012","unstructured":"Wang T, Duncan L, Gu W, O\u2019Dowd H, Wei Y, Perola E, Parsons J, Gross CH, Moody CS, Arends SJR, Charifson PS. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-amino-pyrido [,3-d]pyrimidin-5(8H)-ones.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1016\/j.bmcl.2012.08.094","volume":"22","author":"Surivet J-P.","year":"2012","unstructured":"Surivet J-P, Lange R, Hubschwerlen C, Keck W, Specklin J-L, Ritz D, Bur D, Locher H, Seiler P, Strasser DS, Prade L, Kohl C, Schmitt C, Chapoux G, Ilhan E, Ekambaram N, Athanasiou A, Knezevic A, Sabato D, Chambovey A, Gaertner M, Enderlin M, Boehme M, Sippel V, Wyss P. Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/156859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:32:47Z","timestamp":1609979567000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/156859\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":168,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,6,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666171106160326","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}